

Prof. Hadiye Derya DURANYILDIZ

Personal Information

Office Phone: [+90 212 414 2434](tel:+902124142434) Extension: 34191

Email: deryady@istanbul.edu.tr

Web: <http://aves.istanbul.edu.tr/1379/>

International Researcher IDs

ORCID: 0000-0002-2820-3227

Publons / Web Of Science ResearcherID: AAC-1650-2020

Yoksis Researcher ID: 126154

Education Information

Doctorate, Istanbul University, Onkoloji Enstitüsü, Turkey 1988 - 1996

Postgraduate, Istanbul University, Onkoloji Enstitüsü, Turkey 1986 - 1988

Undergraduate, Istanbul University, Faculty Of Science, Department of Biology, Turkey 1981 - 1986

Dissertations

Doctorate, Servikal Karsinomlu Hastaların Sitolojik Materyallerinde İnsan Papilloma Virüs Enfeksiyonunun Polimeraz Zincir Reaksiyonu (PCR) Yöntemiyle Araştırılması, Istanbul University, Onkoloji Enstitüsü, Temel Onkoloji Ana Bilim Dalı, 1995

Postgraduate, MİDE KARSİNOMLARINDA TÜMÖR DIŞI MİDE MUKOZA DEĞİŞİKLİKLERİNİN HİSTOPATOLOJİK VE HİSTOKİMYASAL İNCELENMESİ, Istanbul University, Onkoloji Enstitüsü, 1995

Research Areas

Medicine, Health Sciences, Fundamental Medical Sciences, Biochemistry

Academic Titles / Tasks

Professor, Istanbul University, Onkoloji Enstitüsü, Temel Onkoloji Ana Bilim Dalı, 2013 - Continues

Associate Professor, Istanbul University, Onkoloji Enstitüsü, Temel Onkoloji Ana Bilim Dalı, 2010 - 2013

Academic and Administrative Experience

Strateji Planlama Komisyon Üyesi, Istanbul University, Onkoloji Enstitüsü, Teşhis Tedavi Ve Bakım Hizmetleri, 2022 - Continues

Academic Performance D. Board Member, Istanbul University, Onkoloji Enstitüsü, Temel Onkoloji Ana Bilim Dalı, 2019 - Continues

Head of Department, Istanbul University, Onkoloji Enstitüsü, Temel Onkoloji Ana Bilim Dalı, 2013 - Continues

Eğitim Komisyon Üyesi, Istanbul University, Onkoloji Enstitüsü, Teşhis Tedavi Ve Bakım Hizmetleri, 2022 - 2023

Hastane Kalite Kurulu Temsilcisi, Istanbul University, Onkoloji Enstitüsü, Müdürlük, 2018 - 2023

Courses

KANSERDE MAKROMOLEKÜLLER, Doctorate, 2020 - 2021, 2019 - 2020
KANSER BİYOKİMYASI, Doctorate, 2020 - 2021, 2019 - 2020
KANSERDE PROTEİN METABOLİZMASINDAKİ DEĞİŞİKLİKLER, Doctorate, 2019 - 2020
KANSER BİYOKİMYASINA GİRİŞ, Doctorate, 2019 - 2020
BİYOKİMYAYA GİRİŞ, Postgraduate, 2020 - 2021

Advising Theses

Duranyıldız H. D., Kolorektal kanserde ETV4-6 ve Pftin in rolü, Doctorate, F.Aytaç(Student), Continues
Duranyıldız H. D., TRPM4 Proteininin meme kanserinde Rolü, Doctorate, S.Doğan(Student), Continues
Duranyıldız H. D., Meme kanserli hastaların kan ve tükürük örneklerinde cullin7 seviyesinin araştırılması, Doctorate, C.TİLGİN(Student), 2022
Duranyıldız H. D., Prostat kanserli hastalarda FMNL1 ve PAK1 seviyelerinin belirlenmesi, Doctorate, E.BİLGİN(Student), 2021
DURANYILDIZ H. D., AKCİĞER KANSERLİ HASTALARDA HGF, cMET, EGF ve EGFR PROTEİNLERİ VE BU PROTEİNLERİN mRNA DÜZEYLERİNİN BELİRLENMESİ, Doctorate, M.SERİLMEZ(Student), 2016
DURANYILDIZ H. D., Meme Kanserli Hastalarda TIMP-1, HA ve SPARC Düzeyleri, Postgraduate, C.Tilgen(Student), 2014
DURANYILDIZ H. D., HEPATOSELLÜLER KARSİNOMLU HASTALARDA VEGF IL-6 VE GLİPİKAN-3'ÜN KLİNİK ÖNEMİ, Postgraduate, M.SERİLMEZ(Student), 2011

Jury Memberships

Associate Professor Exam, Associate Professor Exam, İstanbul Üniversitesi, May, 2023
Associate Professor Exam, Associate Professor Exam, İstanbul Üniversitesi, March, 2023
Associate Professor Exam, Associate Professor Exam, İstanbul Üniversitesi, December, 2022
Post Graduate, Post Graduate, Kırşehir Ahi Evran Üniversitesi, October, 2022
Post Graduate, Post Graduate, Kırşehir Ahi Evran Üniversitesi, October, 2022
Doctoral Examination, Doctoral Examination, İstanbul Üniversitesi, December, 2021
Doctoral Examination, Doctoral Examination, İstanbul Üniversitesi, October, 2021
Doctoral Examination, Doctoral Examination, İstanbul Üniversitesi, October, 2021
Doctoral Examination, Doctoral Examination, İstanbul Üniversitesi, June, 2021
Doctoral Examination, Doctoral Examination, İstanbul Üniversitesi, June, 2021
Doctoral Examination, Doctoral Examination, İstanbul Üniversitesi, October, 2019
Associate Professor Exam, Associate Professor Exam, İstanbul Üniversitesi, June, 2018
Associate Professor Exam, Associate Professor Exam, İstanbul Üniversitesi, June, 2018
Associate Professor Exam, Associate Professor Exam, İstanbul Üniversitesi, June, 2018
Associate Professor Exam, Associate Professor Exam, İstanbul Üniversitesi, December, 2017

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Serum nectin-2 and nectin-4 are diagnostic in lung cancer: which is superior?**
Erturk K., Karaman S., Dagolu N., Serilmez M., Duranyildiz D., Tas F.
WIENER KLINISCHE WOCHENSCHRIFT, no.17-18, pp.419-426, 2019 (SCI-Expanded)
- II. **Detection of serum protein and circulating mRNA of cMET, HGF EGF and EGFR levels in lung cancer patients to guide individualized therapy**
Serilmez M., Ozgur E., Karaman S., Gezer U., Duranyildiz D.

CANCER BIOMARKERS, no.2, pp.177-184, 2019 (SCI-Expanded)

- III. **The biological role of LYVE-1 in lung cancer**
Serilmez M., Karaman S., Soydinc H., Ozgur E., Duranyildiz D.
FEBS OPEN BIO, vol.8, pp.318, 2018 (SCI-Expanded)
- IV. **Clinical significance of serum leptin level in patients with gastric cancer**
Tas F., Karabulut S., Erturk K., Duranyildiz D.
EUROPEAN CYTOKINE NETWORK, vol.29, no.2, pp.52-58, 2018 (SCI-Expanded)
- V. **Role of several cytokines and adhesion molecules in the diagnosis and prediction of survival of hepatocellular carcinoma**
Iliaz R., Akyuz U., Tekin D., Serilmez M., Evirgen S., Cavus B., Soydinc H., Duranyildiz D., Karaca C., Demir K., et al.
Arab Journal of Gastroenterology, vol.17, no.4, pp.164-167, 2016 (SCI-Expanded)
- VI. **Clinical significance of serum claudin-1 levels in melanoma patients**
Tas F., Bilgin E., Erturk K., Duranyildiz D.
MELANOMA RESEARCH, vol.26, no.4, pp.377-381, 2016 (SCI-Expanded)
- VII. **Circulating serum levels of angiopoietin-1 and angiopoietin-2 in nasopharynx and larynx carcinoma patients**
Guveli M. E., Duranyildiz D., Karadeniz A., Bilgin E., Serilmez M., Soydinc H. O., Yasasever V.
TUMOR BIOLOGY, vol.37, no.7, pp.8979-8983, 2016 (SCI-Expanded)
- VIII. **Clinical significance of serum caveolin-1 levels in melanoma patients**
Tas F., Karabulut S., Yasasever C. T., Duranyildiz D.
INTERNATIONAL JOURNAL OF DERMATOLOGY, vol.55, no.5, pp.558-562, 2016 (SCI-Expanded)
- IX. **Elevated circulating monocyte chemoattractant protein 1 (MCP-1/CCL-2) level may be an unfavorable predictive factor to platinum- and taxane-based combination chemotherapy in patients with gastric cancer**
Tas F., Karabulut S., Serilmez M., KARABULUT M., Duranyildiz D.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.77, no.1, pp.127-131, 2016 (SCI-Expanded)
- X. **Clinical significance of interleukin-4 and interleukin-18 levels in aggressive non-Hodgkin's lymphoma patients**
Soydinc H., Guney N., Basaran M., Duranyildiz D., Yasasever V.
GENETICS AND MOLECULAR RESEARCH, vol.15, no.3, 2016 (SCI-Expanded)
- XI. **Clinical significance of serum protease activated receptor1 levels in patients with lung cancer**
Erturk K., Tastekin D., Bilgin E., Tas F., Disci R., Duranyildiz D.
European Review for Medical and Pharmacological Sciences, vol.20, no.2, pp.243-249, 2016 (SCI-Expanded)
- XII. **Clinical significance of serum interleukin-18 (IL-18) levels in patients with gastric cancer**
Tas F., Yasasever C. T., Karabulut S., Tastekin D., Duranyildiz D.
BIOMEDICINE & PHARMACOTHERAPY, vol.70, pp.19-23, 2015 (SCI-Expanded)
- XIII. **Serum transforming growth factor-beta1 levels may have predictive and prognostic roles in patients with gastric cancer.**
Tas F., Yasasever C. T., Karabulut S., Tastekin D., Duranyildiz D.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, vol.36, no.3, pp.2097-103, 2015 (SCI-Expanded)
- XIV. **Diagnostic value of serum M30 and M65 in patients with nasopharyngeal carcinoma**
Sen F., Yildiz I., Odabas H., Tambas M., Kilic L., Karadeniz A., Altun M., Ekenel M., Serilmez M., Duranyildiz D., et al.
TUMOR BIOLOGY, vol.36, pp.1039-1044, 2015 (SCI-Expanded)
- XV. **Circulating annexin A2 as a biomarker in gastric cancer patients: Correlation with clinical variables**
Tas F., Yasasever C. T., Karabulut S., Tastekin D., Duranyildiz D.
Biomedicine and Pharmacotherapy, vol.69, pp.237-241, 2015 (SCI-Expanded)
- XVI. **D-dimer and international normalized ratio (INR) are correlated with tumor markers and disease stage in colorectal cancer patients.**
Kilic L., Yildiz I., Sen F. K., ERDEM M. G., Serilmez M., Keskin S., Ciftci R., Karabulut S., ORDU C., Duranyildiz D., et al.
Cancer biomarkers : section A of Disease markers, vol.15, no.4, pp.405-11, 2015 (SCI-Expanded)

- XVII. Clinical significance of serum epidermal growth factor receptor (EGFR) levels in patients with breast cancer**
Tas F., Bilgin E., Karabulut S., Duranyildiz D.
CYTOKINE, vol.71, no.1, pp.66-70, 2015 (SCI-Expanded)
- XVIII. Clinical significance of serum epithelial cell adhesion molecule (EPCAM) levels in patients with lung cancer**
Tas F., Karabulut S., Duranyildiz D.
MOLECULAR AND CELLULAR BIOCHEMISTRY, vol.396, pp.307-312, 2014 (SCI-Expanded)
- XIX. Clinical significance of serum M30 and M65 levels in patients with breast cancer**
Tas F., Karabulut S., Yildiz I., Duranyildiz D.
BIOMEDICINE & PHARMACOTHERAPY, vol.68, no.8, pp.1135-1140, 2014 (SCI-Expanded)
- XX. Clinical significance of serum fibronectin and vitronectin levels in melanoma patients**
Tas F., Karabulut S., Bilgin E., Tastekin D., Duranyildiz D.
MELANOMA RESEARCH, vol.24, no.5, pp.475-479, 2014 (SCI-Expanded)
- XXI. Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) in patients with breast cancer**
Tas F., Karabulut S., Bilgin E., Tastekin D., Duranyildiz D.
TUMOR BIOLOGY, vol.35, no.9, pp.9303-9309, 2014 (SCI-Expanded)
- XXII. Serum levels of vascular cell adhesion molecule-1 (VCAM-1) may have diagnostic, predictive, and prognostic roles in patients with lung cancer treated with platinum-based chemotherapy**
Tas F., Karabulut S., Bilgin E., Duranyildiz D.
TUMOR BIOLOGY, vol.35, no.8, pp.7871-7875, 2014 (SCI-Expanded)
- XXIII. Clinical significance of serum tenascin-C levels in breast cancer**
Tastekin D., Tas F., Karabulut S., Duranyildiz D., Serilmez M., Guveli M., Vatansever S.
TUMOR BIOLOGY, vol.35, no.7, pp.6619-6625, 2014 (SCI-Expanded)
- XXIV. Serum transforming growth factor-beta 1 (TGF-beta 1) levels have diagnostic, predictive, and possible prognostic roles in patients with melanoma**
Tas F., Karabulut S., Yasasever C., Duranyildiz D.
TUMOR BIOLOGY, vol.35, no.7, pp.7233-7237, 2014 (SCI-Expanded)
- XXV. Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy**
Tas F., Karabulut S., Ciftci R., Sen F., Sakar B., Disci R., Duranyildiz D.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.73, no.6, pp.1163-1171, 2014 (SCI-Expanded)
- XXVI. Coagulation tests show significant differences in patients with breast cancer**
Tas F., Kilic L., Duranyildiz D.
TUMOR BIOLOGY, vol.35, no.6, pp.5985-5992, 2014 (SCI-Expanded)
- XXVII. Clinical significance of serum transforming growth factor-beta 1 (TGF-beta 1) levels in patients with epithelial ovarian cancer**
Tas F., Karabulut S., Serilmez M., Ciftci R., Duranyildiz D.
TUMOR BIOLOGY, vol.35, no.4, pp.3611-3616, 2014 (SCI-Expanded)
- XXVIII. Serum levels of macrophage migration-inhibitory factor (MIF) have diagnostic, predictive and prognostic roles in epithelial ovarian cancer patients**
Tas F., Karabulut S., Serilmez M., Ciftci R., Duranyildiz D.
TUMOR BIOLOGY, vol.35, no.4, pp.3327-3331, 2014 (SCI-Expanded)
- XXIX. Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulinlike growth factor binding protein-3 (IGFBP-3) in patients with epithelial ovarian cancer**
Tas F., Karabulut S., Serilmez M., Ciftci R., Duranyildiz D.
TUMOR BIOLOGY, vol.35, no.4, pp.3125-3132, 2014 (SCI-Expanded)
- XXX. Clinical significance of serum epithelial cell adhesion molecule (EPCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in patients with epithelial ovarian cancer**
Tas F., Karabulut S., Serilmez M., Ciftci R., Duranyildiz D.

TUMOR BIOLOGY, vol.35, no.4, pp.3095-3102, 2014 (SCI-Expanded)

- XXXI. **Clinical significance of serum circulating insulin-like growth factor-1 (IGF-1) mRNA in hepatocellular carcinoma**

Karabulut S., Duranyildiz D., Tas F., Gezer U., Akyuz F., Serilmez M., Ozgur E., Yasasever C. T., Vatansever S., Aykan N. F.

TUMOR BIOLOGY, vol.35, no.3, pp.2729-2739, 2014 (SCI-Expanded)

- XXXII. **Increased serum level of epidermal growth factor receptor (EGFR) is associated with poor progression-free survival in patients with epithelial ovarian cancer**

Tas F., Karabulut S., Serilmez M., Ciftci R., Duranyildiz D.

CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.73, no.3, pp.631-637, 2014 (SCI-Expanded)

- XXXIII. **High serum transforming growth factor beta 1 (TGFB1) level predicts better survival in breast cancer**

Ciftci R., Tas F., Yasasever C., Aksit E., Karabulut S., Sen F., Keskin S., Kilic L., Yildiz I., Bozbey H. U., et al.

Tumor Biology, vol.35, no.7, pp.6941-6948, 2014 (SCI-Expanded)

- XXXIV. **Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma**

Tas F., Karabulut S., Bilgin E., Sen F., Yildiz I., Tastekin D., Ciftci R., Duranyildiz D.

TUMOR BIOLOGY, vol.34, no.6, pp.3529-3536, 2013 (SCI-Expanded)

- XXXV. **Clinical significance of serum M30 and M65 levels in melanoma**

Tas F., Karabulut S., Serilmez M., Yildiz I., Sen F., Ciftci R., Duranyildiz D.

MELANOMA RESEARCH, vol.23, no.5, pp.390-395, 2013 (SCI-Expanded)

- XXXVI. **Serum M65 as a Biomarker for Metastatic Renal Cell Carcinoma**

Yildiz I., Sen F., Kilic L., Keskin S., Duranyildiz D., Bilgin E., Disci R., Ekenel M., Darendeliler E., Bavbek S., et al.

CLINICAL GENITOURINARY CANCER, vol.11, no.3, pp.290-296, 2013 (SCI-Expanded)

- XXXVII. **Clinical and prognostic significance of coagulation assays in lung cancer**

Tas F., Kilic L., Serilmez M., Keskin S., Sen F., Duranyildiz D.

RESPIRATORY MEDICINE, vol.107, no.3, pp.451-457, 2013 (SCI-Expanded)

- XXXVIII. **For Which Cancer Types can Neuron-Specific Enolase be Clinically Helpful in Turkish Patients?**

Bilgin E., Dizdar Y., Serilmez M., Soydinc H. O., Yasasever C., Duranyildiz D., Yasasever V.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.14, no.4, pp.2541-2544, 2013 (SCI-Expanded)

- XXXIX. **Markers of Bone Metastases in Breast and Lung Cancers**

Bilgin E., Yasasever V., Soydinc H. O., Yasasever C., Ozturk N., Duranyildiz D.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.13, no.9, pp.4331-4334, 2012 (SCI-Expanded)

- XL. **Utility of Serum and Urine uPAR Levels for Diagnosis of Breast Cancer**

Soydinc H. O., Duranyildiz D., Guney N., Derin D., Yasasever V.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.13, no.6, pp.2887-2889, 2012 (SCI-Expanded)

- XLI. **Lack of Diagnostic Potential of Dickkopf-1 in Colon and Rectum Cancers**

Soydinc H. O., Duranyildiz D., Camlica H., Oral E. N., Yasasever V.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.12, no.12, pp.3187-3189, 2011 (SCI-Expanded)

- XLII. **Serum levels of angiogenic factors in early breast cancer remain close to normal**

Duranyildiz D., Camlica H., Soydinc H. O., Derin D., Yasasever V.

BREAST, vol.18, no.1, pp.26-29, 2009 (SCI-Expanded)

- XLIII. **Circulating levels of vascular endothelial growth factor (VEGF), matrix metalloproteinase-3 (MMP-3), and BCL-2 in malignant melanoma**

Tas F., Duranyildiz D., Oguz H., Camlica H., Yasasever V., Topuz E.

MEDICAL ONCOLOGY, vol.25, no.4, pp.431-436, 2008 (SCI-Expanded)

- XLIV. **Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases**

Tas F., Duranyildiz D., Oguz H., Camlica H., Yasasever V., Topuz E.

MEDICAL ONCOLOGY, vol.25, no.3, pp.346-349, 2008 (SCI-Expanded)

- XLV. **Serum levels of intercellular adhesion molecule ICAM-1 and E-selectin in advanced stage non-small cell lung cancer**

Guney N., Soydinc H. O., Derin D., Tas F., Camlica H., Duranyildiz D., Yasasever V., Topuz E.

MEDICAL ONCOLOGY, vol.25, no.2, pp.194-200, 2008 (SCI-Expanded)

- XLVI. **Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer**
Tas F., Duranyildiz D., Soydinc H. O., Cicin I., Selam M., Uygun K., Disci R., Yasasever V., Topuz E.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.61, no.5, pp.721-725, 2008 (SCI-Expanded)
- XLVII. **The diagnostic value of macrophage migration inhibitory factor (MIF) in gastric cancer**
Camlica H., Duranyildiz D., Oguz H., Oral E. N., Yasasever V.
PATHOLOGY & ONCOLOGY RESEARCH, vol.14, no.1, pp.79-83, 2008 (SCI-Expanded)
- XLVIII. **Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer**
Derin D., Soydinc H. O., Guney N., Tas F., Camlica H., Duranyildiz D., Yasasever V., Topuz E.
LUNG CANCER, vol.59, no.2, pp.240-245, 2008 (SCI-Expanded)
- XLIX. **Macrophage migration inhibitory factor in cancer**
Yasasever V., Camlica H., Duranyildiz D., Oguz H., Tas F., Dalay N.
CANCER INVESTIGATION, vol.25, no.8, pp.715-719, 2007 (SCI-Expanded)
- L. **Serum IL-8 and IL-12 levels in breast cancer**
Derin D., SOYDINC H. O., Güney N., Tas F., Çamlıca H., Duranyıldız D., Yasasever V., Topuz E.
MEDICAL ONCOLOGY, vol.24, no.2, pp.163-168, 2007 (SCI-Expanded)
- LI. **Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients**
Tas F., Duranyıldız D., OĞUZ H., Çamlıca H., Yasasever V., Topuz E.
MELANOMA RESEARCH, vol.16, no.5, pp.405-411, 2006 (SCI-Expanded)
- LII. **Serum vascular endothelial growth factor (VEGF) and Bcl-2 levels in advanced stage non-small cell lung cancer**
Tas F., Duranyıldız D., OĞUZ H., Çamlıca H., Yasasever V., Topuz E.
CANCER INVESTIGATION, vol.24, no.6, pp.576-580, 2006 (SCI-Expanded)
- LIII. **Serum vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) levels in small cell lung cancer**
Tas F., DURANYILDIZ D., Oguz H., CAMLICA H., YASASEVER V., TOPUZ E.
CANCER INVESTIGATION, vol.24, no.5, pp.492-496, 2006 (SCI-Expanded)
- LIV. **Molecular detection of squamous cell carcinoma antigen transcripts in peripheral blood of cancer patients**
Buyru N., Tigli H., Duranyildiz D., Dalay N.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, vol.44, no.5, pp.538-541, 2006 (SCI-Expanded)
- LV. **Serum and urine survivin levels in breast cancer**
Güney N., SOYDINE H., DEFIN D., Tas F., Çamlıca H., Duranyıldız D., Yasasever V., Topuz E.
MEDICAL ONCOLOGY, vol.23, no.3, pp.335-339, 2006 (SCI-Expanded)
- LVI. **The value of serum Bcl-2 levels in advanced lung cancer patients**
TAS F., DURANYILDIZ D., OGUZ H., CAMLICA H., ORAL E., Yasasever V., TOPUZ E.
MEDICAL ONCOLOGY, vol.22, no.2, pp.139-143, 2005 (SCI-Expanded)
- LVII. **Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 in patients with malignant melanoma**
TAS F., DURANYILDIZ D., OGUZ H., DISCI R., KURUL S., Yasasever V., TOPUZ E.
MEDICAL ONCOLOGY, vol.22, no.1, pp.39-44, 2005 (SCI-Expanded)
- LVIII. **Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer**
TAS F., DURANYILDIZ D., ARGON A., OGUZ H., CAMLICA H., Yasasever V., TOPUZ E.
MEDICAL ONCOLOGY, vol.22, no.4, pp.353-358, 2005 (SCI-Expanded)
- LIX. **The value of serum levels of IL-6, TNF-alpha, and erythropoietin in metastatic malignant melanoma**
TAS F., OGUZ H., ARGON A., DURANYILDIZ D., CAMLICA H., Yasasever V., TOPUZ E.
MEDICAL ONCOLOGY, vol.22, no.3, pp.241-246, 2005 (SCI-Expanded)
- LX. **Serum bcl-2 and survivin levels in melanoma**

TAS F., DURANYILDIZ D., ARGON A., OGUZ H., CAMLICA H., Yasasever V., TOPUZ E.

MELANOMA RESEARCH, vol.14, no.6, pp.543-546, 2004 (SCI-Expanded)

- LXI. **Detection of circulating melanoma cells by a two-marker polymerase chain reaction assay in relation to therapy.**
Bitisik O., Camlica H., Duranyildiz D., Tas F., Kurul S., Dalay N.
Journal of biochemistry and molecular biology, vol.36, no.2, pp.173-8, 2003 (SCI-Expanded)
- LXII. **Prognostic significance of melanoma inhibiting activity levels in malignant melanoma.**
Meral R., Duranyildiz D., Tas F., Camlica H., Yasasever V., Kurul S., Dalay N.
Melanoma research, vol.11, no.6, pp.627-32, 2001 (SCI-Expanded)
- LXIII. **Serum c-erb B2 oncoprotein levels are elevated in recurrent and metastatic breast cancer**
Yasasever V., Dincer M., Camlica H., Duranyildiz D., Dalay N.
CLINICAL BIOCHEMISTRY, vol.33, no.4, pp.315-317, 2000 (SCI-Expanded)
- LXIV. **Serum levels of the soluble adhesion molecules in patients with malignant melanoma**
YASASEVER F. V., TAŞ F., DURANYILDIZ H. D., Çamlıca H., KURUL S., DALAY M. N.
PATHOLOGY & ONCOLOGY RESEARCH, vol.6, no.1, pp.42-45, 2000 (SCI-Expanded)
- LXV. **Serum NSE levels in the Turkish population**
Yasasever V., Meral R., Camlica H., Duranyildiz D., Dalay N.
JOURNAL OF TUMOR MARKER ONCOLOGY, vol.14, no.3, pp.35-40, 1999 (SCI-Expanded)
- LXVI. **Diagnostic value of the PSA subfractions, acid phosphatase and creatine kinase isoenzymes in prostate cancer**
Duranyildiz D., Camlica H., Yasasever V., Ozcan F., Dalay N.
JOURNAL OF TUMOR MARKER ONCOLOGY, vol.14, no.1, pp.39-46, 1999 (SCI-Expanded)
- LXVII. **Evaluation of phosphohexose isomerase as a metastasis marker in breast cancer patients**
Yasasever V., Dincer M., Camlica H., Duranyildiz D., Dalay N.
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, vol.18, no.5, pp.397-399, 1997 (SCI-Expanded)
- LXVIII. **Detection of HPV 16 and HPV 18 infection in patients with cervical neoplasia**
DURANYILDIZ H. D., YAZICI ÖZBEK H., ALATLI F. C., AĞAOĞLU F., ASLAY I., ONAT H., DALAY M. N.
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, vol.17, no.4, pp.296-298, 1996 (SCI-Expanded)
- LXIX. **Serum Levels of Mutant p53 Protein in Cancer**
DURANYILDIZ H. D., YASASEVER F. V., KİZİR A., DALAY M. N.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, vol.15, no.4, pp.335-340, 1996 (SCI-Expanded)
- LXX. **The value of TPS in breast cancer.**
DURANYILDIZ H. D., YASASEVER F. V., ERTÜRK N., DALAY M. N.
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, vol.16, no.5, pp.363-367, 1995 (SCI-Expanded)
- LXXI. **Diagnostic value of the tumor markers in breast cancer**
YASASEVER F. V., DURANYILDIZ H. D., ERTÜRK N., DALAY M. N.
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, vol.15, no.1, pp.33-36, 1994 (SCI-Expanded)
- LXXII. **Acute Coagulation Changes During Cytotoxic Chemotherapy**
ONAT H., BAVBEK S., DURANYILDIZ H. D., ERTÜRK N., DALAY M. N., YASASEVER F. V.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, vol.13, no.1, pp.89-94, 1994 (SCI-Expanded)
- LXXIII. **Cancer Associated Marker Proteins in Benign and Tumor Tissue of Breast Cancer Patients**
YASASEVER F. V., DURANYILDIZ H. D., YAZICI ÖZBEK H., OLGAÇ N. V., DALAY M. N.
JOURNAL OF TUMOR MARKER ONCOLOGY, vol.8, no.4, pp.33-38, 1993 (SCI-Expanded)

Articles Published in Other Journals

- I. **Serum Glypican-3, Vascular Endothelial Growth Factor, and Interleukin-6 Levels in Hepatocellular Carcinoma**
Serilmez M., Akyuz F., Ormeci Ciftcibasi A., Karabulut S., Kaymakoglu S., Yasasever V., Duranyildiz D.
TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, vol.33, no.1, pp.18-27, 2018 (ESCI)

- II. **Significance of serum neural precursor cell-expressed developmentally downregulated protein 9 in melanoma**
Erturk K., Tas F., Serilmez M., Bilgin E., Duranyildiz D.
MOLECULAR AND CLINICAL ONCOLOGY, vol.8, no.1, pp.204-208, 2018 (ESCI)
- III. **Effect of intraperitoneal cetuximab administration on colonic anastomosis and early postoperative adhesion formation in a rat model**
Kurt A., Karanlik H., Soylu S., Ozgur I., Soydinc H. O., Duranyildiz D., Olgac V., Sen F., Asoglu O.
TURKISH JOURNAL OF SURGERY, vol.32, no.3, pp.157-161, 2016 (ESCI)
- IV. **Clinical significance of serum laminin and type-IV collagen levels in cutaneous melanoma patients**
Tas F., Bilgin E., Karabulut S., Duranyildiz D.
MOLECULAR AND CLINICAL ONCOLOGY, vol.5, no.1, pp.195-200, 2016 (ESCI)
- V. **Clinical significance of serum Protease-Activated Receptor-1 (PAR-1) levels in patients with cutaneous melanoma**
Tas F., Bilgin E., Karabulut S., Erturk K., Duranyildiz D.
BBA CLINICAL, vol.5, pp.166-169, 2016 (ESCI)
- VI. **Serum IGF-1 and IGFBP-3 levels as clinical markers for patients with lung cancer**
Tas F., Bilgin E., Tastekin D., Erturk K., Duranyildiz D.
BIOMEDICAL REPORTS, vol.4, no.5, pp.609-614, 2016 (ESCI)
- VII. **Levels of serum fibronectin as a biomarker in gastric cancer patients: Correlation with clinical diagnosis and outcome**
Tas F., Bilgin E., Karabulut S., Tastekin D., Duranyildiz D.
MOLECULAR AND CLINICAL ONCOLOGY, vol.4, no.4, pp.655-659, 2016 (ESCI)
- VIII. **Clinical significance of serum protease-activated receptor-1 levels in gastric cancer patients**
Tas F., Karabulut S., Tastekin D., Duranyildiz D.
BIOMEDICAL REPORTS, vol.4, no.4, pp.489-492, 2016 (ESCI)
- IX. **Clinical significance of serum laminin levels in patients with lung cancer**
Tas F., Bilgin E., Tastekin D., Erturk K., Duranyildiz D.
BIOMEDICAL REPORTS, vol.4, no.4, pp.485-488, 2016 (ESCI)
- X. **Angiogenic factors in small veil lung cancer (VEGF, VEGFR-1, VEGFR-2)**
OĞUZ SOYDİNÇ H., DURANYILDIZ H. D., Bilgin E., TAŞ F., Yasasever V.
TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, vol.27, no.2, pp.55-61, 2012 (ESCI)
- XI. **Hematological parameters in lung cancer**
SERİLMEZ M., OĞUZ SOYDİNÇ H., Camlica H., Topuz E., DURANYILDIZ H. D.
TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, vol.25, no.3, pp.87-92, 2010 (ESCI)
- XII. **Matriks Metalloproteinazlar ve Akciğer Kanseri**
OĞUZ H., Çamlıca H., DURANYILDIZ H. D., KAYTAN SAĞLAM E., TAŞ F., YASASEVER F. V., DALAY M. N., OĞUZ SOYDİNÇ H.
TÜRK ONKOLOJİ DERGİSİ, vol.21, no.2, pp.53-56, 2006 (Peer-Reviewed Journal)
- XIII. **Matrix metalloproteinases and lung cancer**
OĞUZ SOYDİNÇ H., Camlica H., DURANYILDIZ H. D., KAYTAN SAĞLAM E., TAŞ F., Yasasever V., Dalay N.
TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, vol.21, no.2, pp.53-56, 2006 (ESCI)
- XIV. **Küçük Hücreli Dışı Akciğer Kanseri ve Free-HCG**
DURANYILDIZ H. D., OĞUZ H., Çamlıca H., Oral E. N., YASASEVER F. V., DALAY M. N.
TÜRK ONKOLOJİ DERGİSİ, vol.20, no.4, pp.22-25, 2005 (ESCI)
- XV. **MALIGNANT MELANOMA AND SURVIVIN**
Oguz H., DURANYILDIZ H. D., Camlica H., TAŞ F., Yasasever V., Topuz E.
TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, vol.20, no.1, pp.27-29, 2005 (ESCI)
- XVI. **Is Free Beta Human Chorionic Gonadotropin A Useful Tumor Marker in Lung Cancer?**
ORAL E. N., KİZİR A., DURANYILDIZ D., Çamlıca H., DEMOKAN S., YASASEVER V., DALAY N.
JOURNAL OF TUMOR MARKER ONCOLOGY, vol.19, no.5, pp.337-340, 2004 (Peer-Reviewed Journal)
- XVII. **Protein 90K, ICAM1, P-Selectin and Neopterin Levels in Turkish Breast Cancer Patients**

YASASEVER F. V., DURANYILDIZ H. D., DİNÇER M., Çamlıca H., DEMOKAN İŞHAĞOĞLU S., DALAY M. N.
JOURNAL OF TUMOR MARKER ONCOLOGY, vol.19, no.3, pp.199-205, 2004 (Peer-Reviewed Journal)

XVIII. Meme Kanserinde IL8'in Önemi

DURANYILDIZ H. D., OĞUZ H., Çamlıca H., YASASEVER F. V., DALAY M. N., OĞUZ SOYDİNÇ H.
TÜRK ONKOLOJİ DERGİSİ, vol.18, no.4, pp.134-136, 2003 (ESCI)

XIX. Age Adjusted PSA and Serum Prostate-Specific Antigem Levels in the Turkish Population

Çamlıca H., DURANYILDIZ H. D., YASASEVER F. V., DALAY M. N.
JOURNAL OF TUMOR MARKER ONCOLOGY, vol.17, no.3, pp.147-152, 2002 (Peer-Reviewed Journal)

XX. Serum Total Antioxidant Levels are Loe in Cancer Patients

YASASEVER F. V., DURANYILDIZ H. D., DİNÇER M., Çamlıca H., Oral E. N., CENGİZ M., DALAY M. N.
RESEARCH COMMUNICATIONS IN BIOCHEMISTRY AND CELLULAR AND MOLECULAR BIOLOGY, vol.4, pp.277-284,
2001 (Peer-Reviewed Journal)

XXI. Akciğer Kanserlerinde CYFRA 21.1, DNA ve TPS Düzeylerinin Araştırılması

DURANYILDIZ H. D., KİZİR A., YASASEVER F. V., DALAY M. N.
TÜRK ONKOLOJİ DERGİSİ, vol.11, no.1, pp.54-56, 1996 (ESCI)

XXII. Fluorourasil Kardiotoksitesitesi ve Pıhtılaşma Parametreleri ile Kardiotoksitesitenin İlişkisi

BAVBK S., ONAT H., ADALET K., YASASEVER F. V., DURANYILDIZ H. D., DALAY M. N., Topuz E.
TÜRK ONKOLOJİ DERGİSİ, vol.11, no.1, pp.6-13, 1996 (ESCI)

XXIII. Serum neu Oncoproein Levels in Breast Cancer

YASASEVER F. V., DURANYILDIZ H. D., YAZICI ÖZBEK H., ONAT H., DALAY M. N.
JOURNAL OF TUMOR MARKER ONCOLOGY, vol.7, no.2, pp.33-43, 1992 (Peer-Reviewed Journal)

Refereed Congress / Symposium Publications in Proceedings

I. Prognostic Importance of BRAF and PTEN Proteins in Patients with Malignant Melanoma

Bilgin Doğru E., Tilgen Yasasever C., Serilmez M., Taş F., Duranyıldız H. D., Oğuz Soydinc H.
IX. INTERNATIONAL CONGRESS OF MOLECULAR MEDICINE "MOLECULAR MEDICINE IN LIFE SCIENCES", İstanbul,
Turkey, 18 - 20 December 2023, pp.1

II. MEME KANSERİNDE SERUM DOUBLECORTİN-LİKE KİNASE 1DÜZEYLERİ

ÖZTÜRK N., KARADENİZ E., DURANYILDIZ H. D., SERİLMEZ M., OĞUZ SOYDİNÇ H., ÖZTÜRK G., AKÇAY M. N., BAKAN
N.
UluslararasıLaboratuvar Tıbbıve XX. Ulusal KlinikBiyokimya Kongresi, Turkey, 25 - 26 December 2020

III. The biological role of AKT serine/threonine kinase 2 in lung cancer

Serilmez M., Karaman S., Soydinc H. O., Yasasever C., Bilgin E., Duranyildiz D., Yasasever V.
ECCO European Cancer Congress, Amsterdam, Netherlands, 27 - 30 January 2017, vol.72

IV. Do serum nestin levels have a diagnostic effect in patients with colorectal cancer?

KARABULUT S., Serilmez M., Soydinc H., Duranyildiz D.
41st FEBS Congress on Molecular and Systems Biology for a Better Life, Kusadasi, Turkey, 3 - 08 September 2016,
vol.283, pp.115

V. The role of cytokines and adhesion molecules in hepatocellular carcinoma to predict survival

Akyuz F., Iliaz R., AKYUZ U., Duranyildiz D., Serilmez M., Karaca C., Demir K., Besisik F., Kaymakoglu S.
66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), San-Francisco, Costa
Rica, 13 - 17 November 2015, vol.62

VI. Serum MCP-1 in pancreatic adenocarcinoma

Soydinc H., Serilmez M., Karabulut S., Duranyildiz D., Yasasever V.
40th Congress of the Federation-of-European-Biochemical-Societies (FEBS) - The Biochemical Basis of Life, Berlin,
Germany, 4 - 09 July 2015, vol.282, pp.261

VII. Do serum nectin-2 levels have a prognostic effect in patients with colorectal cancer?

Serilmez M., Duranyildiz D., Soydinc H., Karabulut S., Yasasever V.
40th Congress of the Federation-of-European-Biochemical-Societies (FEBS) - The Biochemical Basis of Life, Berlin,

Germany, 4 - 09 July 2015, vol.282, pp.257

- VIII. **Serum NEDD9 levels may have prognostic roles in patients with gastric cancer**
Duranyildiz D., Serilmez M., Soydinc H. O., Karabulut S., Yasasever V.
40th Congress of the Federation-of-European-Biochemical-Societies (FEBS) - The Biochemical Basis of Life, Berlin, Germany, 4 - 09 July 2015, vol.282, pp.253-254
- IX. **OMENTIN LEVELS IN COLON CANCER**
Serilmez M., Ciftci R., BİLGİN DOĞRU E., DURANYILDIZ H. D.
IFCC WorldLAB Istanbul 2014, İstanbul, Turkey, 22 - 26 June 2014, pp.464
- X. **DO THE MATRIX METALLOPROTEASES HAVE ANY EFFECT ON EPITHELIAL OVARIAN TUMORS?**
BİLGİN DOĞRU E., Serilmez M., ÖZTÜRK N., DURANYILDIZ H. D., YASASEVER F. V.
IFCC WorldLAB Istanbul 2014, İstanbul, Turkey, 22 - 26 June 2014, pp.371
- XI. **THE IMPORTANCE OF CEA IN COLON CANCER**
Aksit E., TİLGİN YASASEVER C., ÖZTÜRK N., DURANYILDIZ H. D., YASASEVER F. V.
IFCC WorldLab, İstanbul, Turkey, 22 - 26 June 2014, pp.363
- XII. **Clinical significance of serum epithelial cell adhesion molecule (EPCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in lung cancer.**
KARABULUT S., Tastekin D., CİFTÇİ R., Tambas M., DAGOĞLU N., Guveil M. E., Tas F., Duranyildiz D., Aydiner A.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- XIII. **Clinical significance of serum caveolin-1 levels in melanoma.**
Tastekin D., KARABULUT S., DURANYILDIZ D., Tas F.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- XIV. **Serum Transforme Edici Büyüme Faktörü-Beta1 (TGF-B1) Seviyelerinin Epitelyal Over Kanserli Hastalarda Klinik Önemi**
Karabulut S., Ciftci R., Tastekin D., VATANSEVER S., TAŞ F., TİLGİN YASASEVER C., DURANYILDIZ H. D., Aydiner A., SAİP P. M.
5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.421
- XV. **Meme Kanserli Hastalarda Serum MIF (Macrophage Migration Inhibitory Factor) Düzeylerinin Klinik Açısından Önemi**
Ciftci R., Karabulut S., TİLGİN YASASEVER C., Aksit E., Yıldız I., BİLGİN DOĞRU E., Tas F., Vatansever S., Keskin S., VATANSEVER S., et al.
5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.501
- XVI. **Epitelya Over Kanserli Hastalarda Serum İnsulin-Like Growth Factor (IGF-1) ve İnsulin-Like Growth Factor Binding Protein-3'ün Klinik Önemi**
Tastekin D., Karabulut S., Tas F., Ciftci R., TİLGİN YASASEVER C., DURANYILDIZ H. D.
5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.571
- XVII. **Akciğer Karsinomlu Hastalarda VCAM-1 ve EPCAM Serum Konsantrasyonlarının Klinik Önemi**
Tastekin D., Karabulut S., TAŞ F., Ciftci R., TİLGİN YASASEVER C., DURANYILDIZ H. D.
5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.572
- XVIII. **Meme Kanserli Hastalarda Serum Par-1 (Protease Activated Receptor-1) Düzeylerinin Klinik Açısından Önemi**
Ciftci R., Karabulut S., Aksit E., TAŞ F., TİLGİN YASASEVER C., VATANSEVER S., DURANYILDIZ H. D., Kilic L.
5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.500
- XIX. **Leptin levels in breast cancer**
Serilmez M., Soydinc H. O., Bilgin E., Yasasever C., Duranyildiz D.
22nd IUBMB Congress/37th FEBS Congress, Sevilla, Spain, 4 - 09 September 2012, vol.279, pp.101-102
- XX. **What kind of a role may play IFN-gamma and emmprin in head and neck cancers?**
Bilgin E., Serilmez M., Duranyildiz D., Yasasever V.
36th FEBS Congress of the Biochemistry for Tomorrows Medicine, Torino, Italy, 25 - 30 June 2011, vol.278, pp.197
- XXI. **Angiogenesis markers in nasopharynx and larynx cancers**

Serilmez M., Bilgin E., Yasasever V., Duranyildiz D.

36th FEBS Congress of the Biochemistry for Tomorrows Medicine, Torino, Italy, 25 - 30 June 2011, vol.278, pp.233

XXII. Baş-Boyun kanserlerinde EMMPRIN'in önemi

BİLGİN E., DURANYILDIZ H. D., Serilmez M., ŞEN F., YASASEVER F. V.

19. Ulusal Kanser Kongresi, Antalya, Turkey, 20 - 24 April 2011, pp.1

XXIII. Serum and urine survivin levels in breast cancer

Güney N., SOYDINE H., Derin D., Tas F., Çamlıca H., Duranyıldız D., Yasasever V., Topuz E.

31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.89

XXIV. Chemotherapy Induced Changes in Neopterin and 90K Protein Levels

YASASEVER V., Çamlıca H., TAŞ F., DEMOKAN S., DURANYILDIZ D., KURUL S., DALAY N.

17th International Conference of Human Tumor Marker, China, 1 - 04 March 2000, vol.15, no.1, pp.39

XXV. Kanserli Hastalarda Total Antioksidan Vitamin A ve E düzeyleri.

YASASEVER F. V., DURANYILDIZ H. D., Oral E. N., CENGİZ M., Çamlıca H., DALAY M. N.

The first international Bioscience Days, Antalya, Turkey, 20 - 24 September 1999, pp.578

Supported Projects

ORAL E. N., DAĞOĞLU SAKİN R. N., DURANYILDIZ H. D., KARAMAN Ş., SERİLMEZ M., GEZER U., Project Supported by Higher Education Institutions, akciğer kanserlerinde hepsin molekülünün önemi, 2017 - Continues

DURANYILDIZ H. D., TILGEN YASASEVER C., Project Supported by Higher Education Institutions, Meme Kanserli Hastaların Kan ve Tükürük Örneklerinde Cullin7 Seviyesinin Araştırılması, 2018 - 2023

TAŞ F., DURANYILDIZ H. D., OĞUZ SOYDİNÇ H., Project Supported by Higher Education Institutions, MALİGN MELANOMLU HASTALARDA BRAF VE PTEN PROTEİNLERİNİN PROGNOSTİK ÖNEMİ, 2017 - 2022

DURANYILDIZ H. D., BİLGİN DOĞRU E., YASASEVER F. V., Project Supported by Higher Education Institutions, Prostat Kanserli Hastalarda FMNL1 ve PAK1 Seviyelerinin Belirlenmesi, 2017 - 2021

DURANYILDIZ H. D., OĞUZ SOYDİNÇ H., YASASEVER F. V., SERİLMEZ M., KARAMAN Ş., GEZER U., Project Supported by Higher Education Institutions, Akciğer kanserlerinde ELMO-3'ün Önemi, 2017 - 2020

SERİLMEZ M., OĞUZ SOYDİNÇ H., YASASEVER F. V., DURANYILDIZ H. D., KARAMAN Ş., Project Supported by Higher Education Institutions, Küçük Hücre Dışı Akciğer Kanserlerinde PTEN ve BRAF Moleküllerinin Önemi, 2016 - 2017

DURANYILDIZ H. D., SERİLMEZ M., OĞUZ SOYDİNÇ H., TAŞ F., GEZER U., KIZIR A., Project Supported by Higher Education Institutions, Akciğer Kanserinde LYVE-1'in Önemi, 2015 - 2017

DURANYILDIZ H. D., Project Supported by Higher Education Institutions, Serum NEDD9 levels may have prognostic roles in patients with gastric cancer, 2015 - 2015

DURANYILDIZ H. D., Project Supported by Higher Education Institutions, Meme Kanserli Hastalarda HA, SPARC ve TIMP-1 Düzeyleri, 2013 - 2014

DURANYILDIZ H. D., Project Supported by Higher Education Institutions, HEPATOSELLÜLER KARSİNOMLU HASTALARDA IGF-1 ve HGF'nin Önemi, 2011 - 2012

DURANYILDIZ H. D., Project Supported by Higher Education Institutions, Kolorektal kanserlerde büyüme faktörü ve sitokinlerin önemi, 2010 - 2011

DURANYILDIZ H. D., Project Supported by Higher Education Institutions, Hepatosellüler Karsinomlu Hastalarda VEGF, IL-6 ve GLİPİKAN-3'ün Klinik Önemi, 2009 - 2011

DURANYILDIZ H. D., Project Supported by Higher Education Institutions, NON HODGKİN LENFOMALI HASTA SERUMLARINDA SİTOKİNLERİN VE ANGIOGENİK PARAMETRELERİN KLİNİK ÖNEMLERİNİN ARAŞTIRILMASI, 2008 - 2010

Scientific Refereeing

EXPERIMED, National Scientific Refreed Journal, June 2023

Metrics

Publication: 121

Citation (WoS): 1207

Citation (Scopus): 1282

H-Index (WoS): 20

H-Index (Scopus): 21

Congress and Symposium Activities

21. Ulusal Biyokimya Kongresi, Attendee, İstanbul, Turkey, 2023
- 40th FEBS CONGRESS- The Biochemical Basis of Life, Attendee, Berlin, Germany, 2015
- 22.IUBMB & 37.FEBS Congress, Attendee, Sevilla, Spain, 2012
4. Tıbbi Onkoloji Kongresi, Attendee, Antalya, Turkey, 2012
3. DETAE Günleri, Attendee, İstanbul, Turkey, 2011
36. FEBS Congress, Attendee, Turin, Italy, 2011
19. Ulusal kanser Kongresi, Attendee, Antalya, Turkey, 2011
- 5.International APOCP Conferance, Attendee, İstanbul, Turkey, 2010
- XVIII.Ulusal Kanser Kongresi, Attendee, Antalya, Turkey, 2009
- XVIII. Ulusal Kanser Kongresi, Attendee, Antalya, Turkey, 2009
- 20.Meeting of the European Association for Cancer Research, Attendee, Lyon, France, 2008
- XXIII. IATMO Conferance: Cancer, Cell Death and Differantiation, Attendee, Trieste, Italy, 2007
- XVII. Ulusal Kanser Kongresi, Attendee, Antalya, Turkey, 2007
- II. Ulusal Moleküler Tıp Kongresi, Attendee, İstanbul, Turkey, 2007
- 31.ESMO Congress, Attendee, İstanbul, Turkey, 2006
31. FEBS Congress, Attendee, İstanbul, Turkey, 2006
- I. Tıbbi Onkoloji Kongresi, Attendee, Antalya, Turkey, 2006
- The XXXIII Meeting of the Int Society for Oncodevelopmental Biology and Medicine, Attendee, Rodos, Greece, 2005
- XVI. Ulusal Kanser Kongresi, Attendee, Antalya, Turkey, 2005
- XVI. Ulusal Kanser Kongresi, Attendee, Antalya, Turkey, 2005
- Ulusal Moleküler Tıp Kongresi, Attendee, İstanbul, Turkey, 2005
- 18.Ulusal Biyokimya Kongresi, Attendee, Trabzon, Turkey, 2004
18. Ulusal Biyokimya Kongresi, Attendee, Trabzon, Turkey, 2004
- XV. Ulusal Kanser Kongresi, Attendee, Antalya, Turkey, 2003
- XIV. Ulusal Kanser Kongresi, Attendee, İstanbul, Turkey, 2001
- The Molecular Basis of Cancer :Cell Growth and Death;Keystone Sempesia, Attendee, New Mexico, United States Of America, 2001
- J.Tumour Marker Oncology, Attendee, Honggang, China, 2000
- J. Tumour Marker Oncology, Attendee, Budapest, Hungary, 1999
- XIII.Ulusal Kanser Kongresi, Attendee, Antalya, Turkey, 1999
- The FirstInternational Biosciences Days, Attendee, Antalya, Turkey, 1999
- XIV.Ulusal Biyokimya Kongresi ve Klinik Laboratuar Otomasyon Sempozyumu, Attendee, İzmir, Turkey, 1997
- XII. Ulusal Kanser Kongresi, Attendee, Antalya, Turkey, 1997
- exp biology, Attendee, Louisiana, United States Of America, 1997
- 2ndBalkanMeetingon Human Genetics, Attendee, İstanbul, Turkey, 1996
- XIII.Ulusal Biyokimya Kongresi, Attendee, Antalya, Turkey, 1996

2. Ulusal Meme Hastalıkları Kongresi, Attendee, İstanbul, Turkey, 1995
- XI.Ulusal Kanser Kongresi, Attendee, Antalya, Turkey, 1995
- X. Ulusal Kanser Kongresi, Attendee, İstanbul, Turkey, 1993
4. Kemoterapi Kongresi, Attendee, Bursa, Turkey, 1992
- 11.Ulusal Biyokimya Kongresi, Attendee, Antalya, Turkey, 1992
- IV.Ulusal Biyofizik Kongresi, Attendee, İstanbul, Turkey, 1992